Advance Notice for Sunvepra and Daklinza 2

Sunvepra and DaklinzaSunvepra (asunaprevir) and Daklinza (daclatasvir)** will soon be considered for BC PharmaCare coverage. Therefore, your input will soon be sought.

Tentatively, patient and caregiver input into Sunvepra and Daklinza’s approval process will be requested from Wednesday July 22, 2015 to MIDNIGHT on Wednesday August 19, 2015.

If you are a BC resident and answer yes to any of the following questions, you can give your input into whether or not the treatments should be covered by PharmaCare:

Please note that PharmaCare’s questionnaire for Sunvepra and Daklinza input tentatively wont be available for another three weeks. The Hepatitis C Treatment Information Project will follow this development and keep you updated.

Additional information about Sunvepra (asunaprevir) and Daklinza (daclatasvir) can be found at Asunaprevir and Daclatasvir Advance, a blog post written in January when the Canadian Agency for Drugs and Technologies in Health (CADTH) began reviewing the treatments.

The Canadian Treatment Action Council (CTAC) also has a webinar, created in February 2015, that explains Sunvepra (asunaprevir) and Daklinza (daclatasvir). It includes much more information.

For more information, please contact Your Voice or the Hepatitis C Treatment Information Project.

**Sunvepra (asunaprevir) and Daklinza (daclatasvir) have not yet received Notices of Compliance from Health Canada. They still can not be bought in Canada and are still being reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH). Click here for more information about the drug approval process.